LIVER FIBROSIS
Clinical trials for LIVER FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new LIVER FIBROSIS trials appear
Sign up with your email to follow new studies for LIVER FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Diet or drugs? new study tests if fasting beats pills for fatty liver disease
Disease control ENROLLING_BY_INVITATIONThis study tests whether a Mediterranean diet combined with intermittent fasting can reduce liver scarring (fibrosis) better than the weight-loss medication naltrexone/bupropion. About 70 adults with overweight or obesity and heart or metabolic risks (like type 2 diabetes or high…
Matched conditions: LIVER FIBROSIS
Phase: PHASE4 • Sponsor: Carmen Dietvorst • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
AI spots hidden liver disease in routine scans
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether an AI system can help doctors identify patients with fatty liver disease who need specialist care. About 8,000 adults getting routine CT scans will have their images analyzed by AI to flag those at risk. The goal is to see if AI can improve detection and …
Matched conditions: LIVER FIBROSIS
Phase: NA • Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New drug AZD2389 targets scarred livers in tiny early trial
Knowledge-focused OngoingThis early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is …
Matched conditions: LIVER FIBROSIS
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 23:00 UTC
-
New study tracks blood sugar in liver disease patients on common drug
Knowledge-focused OngoingThis study looks at how a type of medication called PPAR agonists affects blood sugar levels in 30 adults with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will measure changes in blood sugar and other metabolic markers over three months. The goal is to…
Matched conditions: LIVER FIBROSIS
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC